Day One Biopharmaceuticals, Inc.

The momentum for this stock is not very good. Day One Biopharmaceuticals, Inc. is not a good value stock. Day One Biopharmaceuticals, Inc. is not a good growth stock. Day One Biopharmaceuticals, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Day One Biopharmaceuticals, Inc..

News

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Update

Zolmax Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the target of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling...\n more…

Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $35.71

Zolmax Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the company, MarketBeat.com...\n more…

Day One Biopharmaceuticals files to sell 12.07M shares of common for holders

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

8,222 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by SG Americas Securities LLC

Ticker Report SG Americas Securities LLC bought a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the second quarter, according to the company in its most recent disclosure with the...\n more…

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Moderate Buy" from Analysts

Zolmax Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the stock...\n more…

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Average Price Target from Brokerages

Ticker Report Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have been given an average rating of "Moderate Buy" by the eight analysts that are covering the company, Marketbeat Ratings...\n more…